Physician profile
Raul A Monzon
NPI 1508885286
$14,785.61
in general payments reported to CMS, 2019-2025
18 companies · $1,811 in 2025
The $1,811 reported for 2025 was more than what 76% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2021: $82.89 · 2022: $383 · 2023: $425 · 2024: $12K · 2025: $1,811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,000 · Travel and Lodging: $3,365 · Food and Beverage: $2,788 · Education: $40.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,000.00 |
| Travel and Lodging | $3,365.20 |
| Food and Beverage | $2,787.99 |
| Education | $40.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elliquence, LLC | $11,030.71 | 2024 | Disc-Fx System |
| Boston Scientific Corporation | $1,436.35 | 2024-2025 | Intracept, General - Pain Management, General - Therapies |
| Stryker Corporation | $499.53 | 2025 | Mild Device Kit, Optablate |
| Abbott Laboratories | $411.60 | 2021-2025 | Proclaim, Eterna |
| Spr Therapeutics, INC | $376.16 | 2022-2024 | Sprint Pns System |
| Curonix LLC | $251.31 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Nalu Medical, INC. | $197.32 | 2021-2022 | |
| Carlsmed, INC. | $131.63 | 2025 | Aprevo |
| Alexion Pharmaceuticals, INC. | $113.85 | 2025 | |
| Novo Nordisk INC | $107.53 | 2025 | Wegovy |
| Stimwave Technologies Incorporated | $83.00 | 2019 | |
| Nevro Corp. | $52.68 | 2019-2022 | |
| Neuros Medical, INC. | $19.72 | 2025 | Altius |
| Medtronic, INC. | $18.04 | 2025 | Inceptiv |
| Bioventus LLC | $17.81 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $15.31 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.18 | 2019 | |
| Relievant Medsystems, INC. | $10.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raul Monzon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.